To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

Clinical trial NCT05351437 · COMPLETED

Trial details

NCT number: NCT05351437
Sponsor: Memo Therapeutics AG
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

SARS-CoV-2 Infection

Start date: 2022-04-26
Primary completion: 2022-09-04
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.